Resumen de The paediatric cancer clinical research landscape in Spain: A 13-year multicentre experience of the new agents group of the spanish society of paediatric haematology and oncology (sehop)
Alba Rubio San Simón, R. Hladun, A. Juan Ribelles, Alicia Castañeda Heredia, Pilar Guerra García, J. Verdu Amoros, María del Mar Andrés, María Adela Cañete Nieto, S. Rives Solà, Antonio Pérez Martínez, Jaume Mora Graupera, Ana Patiño García, Álvaro Lassaletta Atienza, A. Llort, Manuel Ramírez Orellana, C. Mata, Soledad Gallego Melcón, Javier Martín Broto, Ofelia Cruz Martínez, A. Morales La Madrid, P. Rubio, I. Martínez Romera, Ana Fernández-Teijeiro Álvarez, F. J. Bautista Sirvent, Lucas Moreno
Purpose Early phase trials are crucial in developing innovative effective agents for childhood malignancies. We report the activity in early phase paediatric oncology trials in Spain from its beginning to the present time and incorporate longitudinal data to evaluate the trends in trial characteristics and recruitment rates.
Methods Members of SEHOP were contacted to obtain information about the open trials at their institutions. The study period was split into two equal periods for analysis: 2007–2013 and 2014–2020.
Results Eighty-one trials and two molecular platforms have been initiated. The number of trials has increased over the time of the study for all tumour types, with a predominance of trials available for solid tumours (66%). The number of trials addressed to tumours harbouring specific molecular alterations has doubled during the second period. The proportion of industry-sponsored compared to academic trials has increased over the same years. A total of 565 children and adolescents were included, with an increasing trend over the study period. For international trials, the median time between the first country study approval and the Spanish competent authority approval was 2 months (IQR 0–6.5). Fourteen out of 81 trials were sponsored by Spanish academic institutions.
Conclusions The number of available trials, and the number of participating patients, has increased in Spain from 2007. Studies focused on molecular-specific targets are now being implemented. Barriers to accessing new drugs for all ranges of age and cancer diseases remain. Additionally, opportunities to improve academic research are still required in Spain.
